Stay updated with breaking news from Generic Name. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The "CNS Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global CNS...
Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong First Launch For Dayvigo In Asia Outside Of Japan TOKYO, July 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Eisai received approval for DAYVIGO in Hong Kong on February 28, 2021, and this launch is the first fo...
Share this article Share this article ResearchAndMarkets.com's offering. The global market for CNS Therapeutics is projected to reach US$137.7 billion by 2025, driven by the urgent need to address the unmet medical needs of neurological disorders. Diseases of the brain and mind range from epilepsy, stroke, migraine, Alzheimer`s, Parkinson`s, dementia, multiple sclerosis, brain injuries, neuroinfections, schizophrenia, psychosis and other mental disorders. With unmet needs continuing to persist, societal and healthcare burden continues to increase. Stroke and infections such as meningitis and...
New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong First Drug Approval for Dayvigo in Asia Outside of Japan TOKYO, Mar 2, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. This approval is the first approval for DAYVIGO in Asia outside of Japan. DAYVIGO ...
Inadvertent vaccination in pregnancy (VIP) Advice for health professionals on pregnant women who are inadvertently vaccinated against coronavirus (COVID-19), chicken pox (varicella), shingles or measles, mumps, rubella. From: Contents PHE) follows up women who have inadvertently been given certain vaccines in pregnancy ( VIP) across the UK. These women would therefore not have been aware they were pregnant at the time of vaccination. Through GPs and surgeries to better inform: pregnant women who are immunised their families Notify MMR), chicken pox or shingles vaccine inadvertentl...